August 24, 2021
The attorneys who secured an $18.25 million settlement for Esperion Therapeutics investors in a securities class action will be awarded a 32.5% portion of the settlement amount plus expenses in the amount of $833,716.99, according to an order filed in Michigan federal court Tuesday.
April 27, 2021
Investors in Esperion Therapeutics have notified a Michigan federal judge that they've reached an $18.25 million settlement deal with the company that would resolve claims it falsely stated regulators wouldn't be requiring a time-consuming study before approving a new cholesterol drug.
June 01, 2020
A Michigan federal judge on Sunday certified a class of investors accusing Esperion Therapeutics Inc. of falsely stating that the U.S. Food and Drug Administration wouldn't be requiring a time-consuming study before approving a new cholesterol drug, finding that the claims lend themselves well to a class action.